85 related articles for article (PubMed ID: 19857795)
21. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
22. Viracept contaminated in Europe.
AIDS Patient Care STDS; 2007 Jul; 21(7):521. PubMed ID: 17651033
[No Abstract] [Full Text] [Related]
23. A process in need is a process indeed: scalable enantioselective synthesis of chiral compounds for the pharmaceutical industry.
Ikunaka M
Chemistry; 2003 Jan; 9(2):378-88. PubMed ID: 12532286
[TBL] [Abstract][Full Text] [Related]
24. Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals.
Corrigan DK; Whitcombe MJ; McCrossen S; Piletsky S
J Pharm Pharmacol; 2009 Apr; 61(4):533-7. PubMed ID: 19298702
[TBL] [Abstract][Full Text] [Related]
25. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
Elder DP; Snodin DJ
J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
[TBL] [Abstract][Full Text] [Related]
26. Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept, Roche): overview.
Pozniak A; Müller L; Salgo M; Jones JK; Larson P; Tweats D
AIDS Res Ther; 2009 Aug; 6():18. PubMed ID: 19660105
[TBL] [Abstract][Full Text] [Related]
27. Ethyl methanesulphonate in a parenteral formulation of BMS-214662 mesylate, a selective farnesyltransferase inhibitor: formation and rate of hydrolysis.
Nassar MN; Cucolo M; Miller SA
Pharm Dev Technol; 2009; 14(6):672-7. PubMed ID: 19883257
[TBL] [Abstract][Full Text] [Related]
28. Less dose burden for Viracept.
AIDS Patient Care STDS; 2003 Jul; 17(7):365. PubMed ID: 12952738
[No Abstract] [Full Text] [Related]
29. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu DQ; Chen TK; McGuire MA; Kord AS
J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
[TBL] [Abstract][Full Text] [Related]
30. Effect of ethyl methane sulphonate on biomass and protein production by Candida tropicalis.
Mahmoud YA
Cytobios; 1999; 99(391):123-8. PubMed ID: 10582329
[TBL] [Abstract][Full Text] [Related]
31. [Modification of the mutagenic effect of ethylmethane sulfonate by adrenaline].
Semenov VV; Ibragimova MIa; Barabanshchikov BI
Biull Eksp Biol Med; 1998 Oct; 126(10):427-9. PubMed ID: 9825142
[No Abstract] [Full Text] [Related]
32. Recall of AIDS drug hits world's poorest patients.
AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
[No Abstract] [Full Text] [Related]
33. European license for Viracept re-established by EC.
AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338433
[No Abstract] [Full Text] [Related]
34. The profiling of MDMA tablets: a study of the combination of physical characteristics and organic impurities as sources of information.
Milliet Q; Weyermann C; Esseiva P
Forensic Sci Int; 2009 May; 187(1-3):58-65. PubMed ID: 19345026
[TBL] [Abstract][Full Text] [Related]
35. Estimation and characterisation of budesonide tablets impurities.
Ferraboschi P; Bertacche V; Maccone I; Pini E; Ragonesi L; Venturini A; Stradi R
J Pharm Biomed Anal; 2008 Jul; 47(3):636-40. PubMed ID: 18367362
[TBL] [Abstract][Full Text] [Related]
36. Thresholds: absolute, practical, pragmatic, apparent and virtual.
Jeffrey AM
Toxicol Lett; 2009 Dec; 191(2-3):365; author reply 366-7. PubMed ID: 19665532
[No Abstract] [Full Text] [Related]
37. Pfizer warns health care professionals of possible carcinogen in Viracept.
AIDS Read; 2007 Nov; 17(11):528. PubMed ID: 18167635
[No Abstract] [Full Text] [Related]
38. Small-sized human immunodeficiency virus type-1 protease inhibitors containing allophenylnorstatine to explore the S2' pocket.
Hidaka K; Kimura T; Abdel-Rahman HM; Nguyen JT; McDaniel KF; Kohlbrenner WE; Molla A; Adachi M; Tamada T; Kuroki R; Katsuki N; Tanaka Y; Matsumoto H; Wang J; Hayashi Y; Kempf DJ; Kiso Y
J Med Chem; 2009 Dec; 52(23):7604-17. PubMed ID: 19954246
[TBL] [Abstract][Full Text] [Related]
39. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
[TBL] [Abstract][Full Text] [Related]
40. Photoinduced color changes in two different qualities of riboflavin in the solid state and in various tablet formulations photoreactivity of biologically active compounds. XX.
Sue-Chu M; Kristensen S; Tønnesen HH
Pharmazie; 2009 Jul; 64(7):428-35. PubMed ID: 19694178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
